UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
US Judge Dismisses Gautam Adani Criminal Charges 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
ADNOC Gas Targets Up to $4B Profit in 2026 
MOUNTAIN VIEW, Calif., Feb. 20, 2018 -- IRIDEX Corporation (Nasdaq:IRIX) today announced the Company will release financial results for the fourth quarter and full year 2017 after the close of trading on Thursday, March 8, 2018. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 8195624. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.iridex.com. A telephone replay will also be available beginning Thursday, March 8, 2018 through Friday, March 9, 2018 by dialing (855) 859-2056 for domestic callers or (404) 537-3406 for international callers, using conference ID: 8195624.
About IRIDEX
IRIDEX Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.
Investor Relations Contact
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
[email protected]
